2. Disease Areas
  3. Blood or Cardio-cerebrovascular Disease
  4. Cardiovascular Disease
  5. Atherosclerosis

Atherosclerosis

Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of plaques—composed of cholesterol, fat, calcium, and other substances—within the inner lining of arteries, leading to thickening and hardening of the arterial walls. This progressive buildup narrows the arterial lumen, reducing blood flow and potentially causing partial or complete occlusion, which can result in serious complications such as coronary artery disease, stroke, peripheral artery disease, renal artery stenosis, and mesenteric artery ischemia. The condition often begins in childhood and worsens with age, frequently associated with risk factors including high cholesterol, hypertension, smoking, and unhealthy diet. While symptoms such as chest pain, shortness of breath, and fatigue may not appear until significant plaque buildup has occurred, atherosclerosis can ultimately lead to life-threatening events like heart attack or stroke if left untreated. It is a subtype of arteriosclerosis and represents a major underlying cause of cardiovascular morbidity and mortality worldwide.

References:

Atherosclerosis (15):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-D1005
    Poloxamer 407 (F127) 9003-11-6
    Poloxamer 407 (F127) is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8 AM and Quest Rhod-4 AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor.
    Poloxamer 407 (F127)
  • HY-W045271
    Imidazole-5-propionic acid 1074-59-5 99.99%
    Imidazole-5-propionic acid (Imidazolepropionic acid) is a urinary metabolite of L-histidine (HY-N0832). Imidazole-5-propionic acid can be used in the research of intestinal diseases and cardiovascular diseases.
    Imidazole-5-propionic acid
  • HY-18778
    Obicetrapib 866399-87-3 99.93%
    Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
    Obicetrapib
  • HY-110390
    GR148672X 263890-70-6 99.58%
    GR148672X is an inhibitor of carboxylesterase 1 (CES1) and hepatic microsomal triglyceride hydrolase (TGH). GR148672X blocks the catalytic activity of CES1, impairs the functions of triglyceride and cholesteryl ester lipase, reduces triglyceride mobilization and secretion, and decreases apolipoprotein B-100 secretion in primary rat hepatocytes. Under low-glucose conditions, GR148672X inhibits the survival of colorectal cancer cells by reducing free fatty acid availability, inducing toxic triglyceride accumulation, ROS production, mitochondrial damage, ferroptosis and apoptosis. GR148672X can be used in studies related to colorectal cancer and atherosclerosis.
    GR148672X
  • HY-185104
    Ginsenoside C-K hexapropionate ester 2861254-89-7 98.88%
    Ginsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1 by activating LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng saponins, by modification with propionic anhydride.
    Ginsenoside C-K hexapropionate ester
  • HY-182014
    TLC-2716
    TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders.
    TLC-2716
  • HY-P11487
    UTG-4
    UTG-4 is a GLP-1R, GIPR, and GCGR agonist with EC50 values of 126.3 pM, 29.2 pM, and 250.2 pM, respectively. UTG-4 binds to HSA (Kd = 14.6 μM). UTG-4 effectively alleviates endothelial-mesenchymal transition. UTG-4 promotes weight loss, inhibits food intake, improves glucose tolerance, and has a significant anti-atherosclerotic effect.
    UTG-4
  • HY-179373
    UB-MBX-46
    UB-MBX-46 is a potent and selective P2X7 receptor antagonist with IC50s of 0.514 nM (hP2X7R), 40.6 nM (rP2X7R), and 4.52 nM (mP2X7R), respectively. UB-MBX-46 interacts with the classical allosteric pocket of the human P2X7 receptor. UB-MBX-46 can be used for cancer, atherosclerosis, and neurode generation research.
    UB-MBX-46
  • HY-N18066
    Esculeogenin A 854381-37-6
    Esculeogenin A is the sapogenol of tomato saponin Esculeoside A (HY-N18067). Esculeogenin A is an orally active hepatoprotective, hypolipidemic, and antioxidant agent. Esculeogenin A regulates molecular targets like PPARα, SREBP1, Nrf2, NF-κB, ACAT1/ACAT2 to promote hepatic fatty acid oxidation, suppress de novo lipogenesis, enhance antioxidant defense, and inhibit inflammation. Esculeogenin A improves liver function, alleviates hyperlipidemia, and inhibits hepatic steatosis and foam cell formation, preventing nonalcoholic fatty liver disease in high-fat-diet-fed rats and reducing atherosclerotic lesions in apoE-deficient mice. Esculeogenin A can be used for the research of nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia.
    Esculeogenin A
  • HY-181122
    MK169
    MK169 is an IL-1β inhibitor. MK169 reduces LPS (HY-D1056)-induced IL-1β release in human aortic smooth muscle cells. MK169 is applicable to the research of cardiovascular inflammatory diseases such as atherosclerosis.
    MK169
  • HY-P11650
    HE4-1 leech peptide 2531396-44-6
    HE4-1 leech peptide is a p38 MAPK inhibitor with an additional c-Jun N-terminal kinase (JNK) inhibitory role. HE4-1 leech peptide suppresses macrophage migration, and does not significantly affect macrophage immunological activities including phagocytic ability, lysozyme activity, and expression levels of most inflammatory factors. HE4-1 leech peptide can be used for the research of atherosclerosis.
    HE4-1 leech peptide
  • HY-N2423B
    (E/Z)-Sinigrin free base 534-69-0
    (E/Z)-Sinigrin ((E/Z)-Allyl-glucosinolate; (E/Z)-2-Propenyl-glucosinolate) free base is an orally active aliphatic thioglucoside anti-leukemia compound. Allyl isothiocyanate, produced by the hydrolysis of (E/Z)-sinigrin free base by myrosinase, has an IC50 of 2.71 μM against HL60 leukemia cells. The hydrolysis products of (E/Z)-sinigrin free base can further activate apoptosis pathways, inhibit NF-κB and MAPK signaling pathways, and induce phase II metabolic enzyme activity, thus exhibiting anti-cancer, anti-inflammatory, antibacterial, antioxidant, and wound healing activities. (E/Z)-Sinigrin free base can be used in research on cancer, inflammation-related diseases (such as atherosclerosis), and infectious diseases. (E/Z)-Sinigrin free base can be naturally extracted from the seeds of Brassica nigra, Brassica juncea, and other Brassicaceae plants such as broccoli and Brussels sprouts. Methyl pechueloate is a guaiane-type sesquiterpene ester compound and a potential precursor of xerantholide. It is useful in the structural elucidation and biosynthetic pathway studies of sesquiterpenoids. Methyl pechueloate can be naturally extracted from the aerial parts of Pechuel-Loeschea leibnitziae (Kuntze) O. Hoffm.
    (E/Z)-Sinigrin free base
  • HY-134028
    Arucadiol 105037-85-2
    Arucadiol is a rosane-type diterpenoid anti-inflammatory agent. 5 μM Arucadiol significantly inhibits LPS-induced TNF-α, IL-1β, and IL-8 production (inhibition rates of 39.8%, 44.4%, and 34.5%, respectively). Arucadiol exerts its anti-inflammatory activity by inhibiting the mRNA and protein expression of inflammatory cytokines and can be used in research on inflammation-related cardiovascular diseases such as atherosclerosis. Arucadiol can be naturally extracted from the roots of Salvia miltiorrhiza var. alba.
    Arucadiol
  • HY-185008
    CPP11G 1580464-93-2
    CPP11G (Compound 11g) is a highly selective NADPH oxidase 2 (Nox2) inhibitor (IC50=20 μM). CPP11G is promising for research of inflammatory diseases (e.g., vasculitis, atherosclerosis) and Nox2-overactivated pathologies (e.g., ischemia-reperfusion injury).
    CPP11G
  • HY-120849
    Darapladib analog-1 1389264-17-8
    Darapladib analog-1 (Compound 16) is an O-alkylated Darapladib (HY-10521). Darapladib analog-1 inhibits Lp-PLA2. Darapladib analog-1 can be used in the research of atherosclerosis.
    Darapladib analog-1